Rapport Therapeutics (RAPP) closed at $23.72 on November 5, 2026, down 8.5% from the previous close, on volume of 652,742 shares (30-day average 1,133,860).
Data as of November 5, 2026.
TipRanks (Thu, 5-Nov 7:20 AM ET)
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from H.C. Wainwright
TipRanks (Thu, 5-Nov 6:36 AM ET)
Analysts’ Top NA Picks: Figma, Inc. Class A (FIG), Chime Financial, Inc. Class A (CHYM)
TipRanks (Thu, 5-Nov 6:10 AM ET)
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Market Chameleon (Mon, 2-Nov 3:20 AM ET)
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Rapport Prices a $175M Stock Deal and $150M Convertible Notes as It Targets Funding Through 2029
Market Chameleon (Wed, 28-Oct 3:06 AM ET)
Globe Newswire (Wed, 28-Oct 6:00 AM ET)
Globe Newswire (Tue, 27-Oct 4:32 PM ET)
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.
As of November 6, 2026, RAPP stock price climbed to $23.78 with 57,589 million shares trading.
RAPP has a beta of 1.70, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.17 to the broad based SPY ETF.
RAPP has a market cap of $1.41 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
RAPP has underperformed the market in the last year with a price return of -9.1% while the SPY ETF gained +10.1%. RAPP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.0% and -10.4%, respectively, while the SPY returned -3.8% and -3.3%, respectively.
RAPP support price is $22.44 and resistance is $25.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.
